Clinical Trial

Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHD

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The study plan aims to include patients who have been diagnosed with steroid-refractory chronic GVHD in the liver following allogeneic hematopoietic stem cell transplantation. After obtaining informed consent, the patients will receive a treatment regimen consisting of the Anti-CD25 rhMAb in combination with prednisone, cyclosporine, and ruxolitinib.The objective is to assess the effectiveness and safety of Anti-CD25 rhMAb in the treatment of severe chronic GVHD affecting the liver.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-04-12.
Trial Details
NCT Number NCT06364319
Lead Sponsor Peking University People's Hospital
Conditions cGVHD
Enrollment 30 participants
Start Date 2026-07-15
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-18